Kinase inhibitors translate lab discoveries into exciting new cures for cancers
- 1 August 2004
- journal article
- review article
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 71 (8) , 713-718
- https://doi.org/10.1007/bf02730661
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood, 2003
- Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phaseSeminars in Hematology, 2003
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood, 2002
- STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’Leukemia, 2002
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001